Related Experiment Videos

[Definition of therapeutic effect of mildronate in patients with chronic heart failure]

V Chumburidze1, T Kikalishvili, T Sulashvili

  • 1National Centre of Therapy, Tbilisi, Georgia.

Georgian Medical News
|July 1, 2005
PubMed

Insights

Mildronate effectively manages chronic heart failure (CHF) when added to standard treatments. This study shows improved outcomes for CHF patients using mildronate, optimizing cardiac energy metabolism for better results.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Chronic heart failure (CHF) is a leading cause of death and disability in developed nations, affecting 1-2% of the population with increasing prevalence.
  • Current first-line treatments for CHF include ACE inhibitors, beta-blockers, and diuretics.

Purpose of the Study:

  • To investigate the efficacy and safety of mildronate as an add-on therapy for patients with chronic heart failure (CHF) classified as NYHA III-IV functional class.
  • To evaluate mildronate's potential in optimizing cardiac energy metabolism for CHF management.

Main Methods:

  • A study involving 110 patients with CHF, already stable on conventional treatments (diuretics, ACE inhibitors, beta-blockers, digoxin).
  • Patients received additional treatment with mildronate.
  • Assessments included clinical data, changes in functional class (FC), echocardiography, and the 6-minute walk test.

Main Results:

  • Mildronate demonstrated effectiveness as part of a comprehensive treatment strategy for chronic heart failure.
  • The study suggests mildronate is a valuable addition to existing CHF therapies.

Conclusions:

  • Mildronate is an effective drug for the complex management of chronic heart failure (CHF).
  • The findings support the use of mildronate to improve outcomes in CHF patients.

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...